Navigation Links
Moffitt Cancer Center: Growing interest in prognostic test for non-small cell lung cancer
Date:4/26/2010

Tampa, FL (April 23, 2010) Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer.

The ERCC1 Analysis measures ERCC1 levels in cells to predict response to cisplatin-based chemotherapy. The correlation between ERCC1 levels and therapy response was discovered at Moffitt Cancer Center and exclusively licensed to Genzyme Corporation in November of 2007. Genzyme Genetics, a business unit of Genzyme Corporation, officially launched the ERCC1 Analysis on May 1, 2009.

Several studies1-6 have shown that evaluating the expression levels of excision repair cross-complementation group 1 (ERCC1) may help physicians identify patients that may benefit from platinum-based chemotherapy - currently considered the standard of care in advanced NSCLC. Specifically, low expression levels of ERCC1 have been related to a better response and survival benefit from adjuvant cisplatin-based chemotherapy.

"We are very pleased that many medical oncologists have begun utilizing this lung cancer test to better identify chemotherapy for non small cell lung cancer patients," said Jarett Rieger, Director of the Office of Technology Management and Licensing at Moffitt. "This test is an example of personalized medicine emanating from Moffitt Cancer Center, and as a result of our licensing partnership with Genyzme this test can now benefit lung cancer patients."

"The ERCC1 test complements our growing menu of personalized tests that predict response to treatment in NSCLC, said Celeste Chenet-Monte, Director Marketing, Oncology at Genzyme Genetics. "Other tests on our menu include EGFR and KRAS mutation analysis, ALK gene rearrangements and EGFR amplification, all of which can be used for prediction of response to targeted therapies used to treat patients with ad
'/>"/>

Contact: Michelle Foley
Michelle.Foley@moffitt.org
813-745-1505
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Moffitt Cancer Center signs licensing agreement with Proteacel, LLC
2. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
3. A study by the MUHC and McGill University opens a new door to understanding cancer
4. ESF EURYI award winner aims to stop cancer cells reading their own DNA
5. Protein chatter linked to cancer activation
6. Newly created cancer stem cells could aid breast cancer research
7. Western diet linked to increased risk of colon cancer recurrence
8. Obesity and lack of exercise could enhance the risk of pancreatic cancer
9. Low levels of key protein may indicate pancreatic cancer risk
10. Birth records hold pancreatic cancer clue
11. Many parents at-risk for cancer disclose genetic test results to children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2014)... marketing directed at children on the interior and ... the majority of black, middle-income and rural communities ... Authored by Arizona State University researcher Punam Ohri-Vachaspati ... to examine the use of child-directed marketing on ... and its relationship to demographics. It adds to ...
(Date:11/4/2014)...   Neurotechnology , a provider of high-precision ... version of its fingerprint matching algorithm has achieved ... evaluation organized by NIST. The MINEX test measures ... 378 fingerprint standard template format. MINEX compliance is ... the United States and ...
(Date:11/3/2014)... ANGELES , Nov. 3, 2014  NeuroSigma ... -based life sciences company focused on commercialization ... system for the treatment of neurological and ... of Industrial Property has issued a Notice of ... patent application is co-owned by NeuroSigma and the ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... The Gerontological Society of America (GSA) the ... has chosen Pankaj Kapahi, PhD, of the Buck Institute ... Shock New Investigator Award. The distinguished honor is given ... biological research. It was established in 1986 to honor Nathan ...
... An NPL imaging scientist Agnieszka Bialek won the Royal ... spectral imaging. The Selwyn Award is sponsored by ... introduced in 1994 in memory of E W H Selwyn, ... to a scientist under the age of 35 who has ...
... descendents of the first plants that colonized land and ... invasive pests and habitat loss, especially those species endemic ... published recently as the cover article in ... these plants as relicts (leftovers of formerly abundant organisms), ...
Cached Biology News:National Physical Laboratory scientist wins photographic award 2New research on rapidly disappearing ancient plant offers hope for species recovery 2New research on rapidly disappearing ancient plant offers hope for species recovery 3
(Date:11/26/2014)... 2014 Continuing its award-winning streak, Nerium ... prestigious MarCom Awards for outstanding creative achievement by its ... MarCom Award, the organization’s top honor, in the Branding ... held in April of this year. The event showcased ... Additionally, Nerium was awarded a Gold MarCom Award in ...
(Date:11/26/2014)... West Chester, OH (PRWEB) November 25, 2014 ... International Holdings, has joined the Graphel Carbon Products team ... experience in sales, marketing, and customer service for the ... to add Miles to our team,” stated Dave Trinkley, ... Products. “His wide range of experience in the ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 2014 ... is an in-depth research report on the Global ... report introduces Palmitic Acid, basic information, including definition, ... analysis, and news analysis, etc. , For ... Palmitic Acid market in China and ...
(Date:11/26/2014)... TOKYO , 25 novembre 2014 /PRNewswrie/ -- Theravalues ... per il mercato europeo in occasione di Hi Europe ... ). Si tratta della curcumina con ... tecnologia amorfa (senza cristalli) e ingredienti approvati dalle norme ... presente nella spezia della pianta curcumina ( Curcuma longa ...
Breaking Biology Technology:Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3
... BASKING RIDGE, N.J., Aug. 24 Regado ... of antithrombotic therapeutic aptamers with active control agents, today ... Phase I study of a subcutaneous administration formulation of ... randomized, placebo-controlled, single ascending dose study to evaluate safety, ...
... CAMBRIDGE, Mass., Aug 24 Shire plc (LSE: SHP, NASDAQ: ... today that it has entered into a research-based collaboration with ... develop its proprietary Locked Nucleic Acid (LNA) technology in a ... its already strong competitive position for its Human Genetic Therapies ...
... August 24 , - Santaris ... Research,Program Utilizing Santaris Pharma,s Proprietary Locked Nucleic Acid (LNA),Drug Platform ... Treatment of Rare Genetic Disorders , ... and Royalties for Providing Access to its LNA Technology,Exclusivity for ...
Cached Biology Technology:Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System 2Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform 2Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform 3Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform 4Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders 2Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders 3Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders 4
96-well format (For processing samples on microplate-size MALDI target plates such as those from Bruker, Shimadzu, Thermo, and PerkinElmer) Packaging: 2 / pack...
... antibody raised against a partial recombinant IFNA2. ... partial recombinant protein is produced in E. coli. ... IU/ mg. OMIM: 147562, ... Lot Number: MM951100564 MA Code: ...
Mouse monoclonal antibody raised against a partial recombinant CENTB2. NCBI Entrez Gene ID = CENTB2...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
Biology Products: